PDCD1 and glioblastoma: Although single agent activity of IDO inhibitors have not been promising in solid tumours [114], recent reports of significantly higher response rates in combination with PD-1 inhibitors have prompted excitement [115] and this strategy may have utility in combinations for glioblastoma.